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602Abstract: The aim of this randomized, crossover, comparison study was to assess the analgesic and
adverse effects of 2 nasal preparations, intranasal fentanyl (INFS) and fentanyl pectin nasal spray
(FPNS), for breakthrough pain, given in doses proportional to opioid basal regimen. Each patient
randomly received INFS or FPNS in doses proportional to opioid dosages used for background anal-
gesia for 2 pairs of episodes. For each episode of breakthrough pain, pain intensity and adverse ef-
fects intensity were recorded just before starting the INFS or FPNS (T0) and 5 minutes (T5), 10 minutes
(T10), and 20 minutes (T20) after the administration of the nasal drugs. Sixty-nine patients were stud-
ied. The mean age was 63.4 years, and 37 patients were males. For the present analysis, 188 episodes
were considered. A statistical decrease in pain intensity was observed with both nasal drugs after 5,
10, and 20 minutes. A decrease in pain intensity of >33% was observed in 16, 102, and 159 treated
episodes at T5, T10, and T20, respectively. Adverse effects were of mild nature in most cases or
were preexistent because of basal opioid therapy. No differences were found in summed pain inten-
sity difference 20 minutes after dosing. Most of patients did not find substantial preferences. INFS
and FPNS were effective and well-tolerated treatments for breakthrough pain management. Both de-
livery systems, in doses proportional to the basal opioid regimen, provided significant analgesia
within 10 minutes, without producing relevant adverse effects.
Perspective: This article showed that INFS and FPNS in doses proportional to basal opioid regimen
are equally safe and effective for the management of breakthrough pain in cancer patients. These
data provide new insights on the use of nasal preparations of fentanyl.
ª 2014 by the American Pain Society
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.doi.org/10.1016/j.jpain.2014.02.002a transitory increase in pain intensity on a baseline
pain of moderate intensity in patients on analgesic
treatment regularly administered.1,26 More recently, it
has been underlined that background pain should be
of mild intensity.3 Many transmucosal fentanyl products
have been licensed for BTP in opioid-tolerant patients.21
These preparations, named rapid-onset opioids (ROOs),
have some advantages such as ease of administration,
rapid onset of action, and avoidance of first-pass meta-
bolism, which consequently offer an interesting alterna-
tive to intravenous, subcutaneous, oral, and rectal
administration in the management of BTP. A recent
meta-analysis of the efficacy of opioid analgesics in the
management of BTP episodes has reported that these
fentanyl preparations achieved a greater level of pain
Mercadante et al The Journal of Pain 603relief in a shorter time frame than placebo and oral
opioids.11
Intranasal administration is a noninvasive route for
drug delivery, which is widely used for many drugs.
Because drugs can be absorbed into the systemic
circulation through the nasal mucosa, this route may
also be used in patients with buccal problems, including
mucositis or dry mouth.8 There are 2 approved nasal fen-
tanyl products. Intranasal fentanyl (INFS) comprises an
aqueous-buffered solution containing fentanyl citrate
equivalent to .5, 1, or 2 mg/mL of fentanyl base.7,8 The
product provides fentanyl doses of 50, 100, and 200 mg.
Fentanyl pectin nasal spray (FPNS) is an aqueous
solution that is based on a delivery system to provide in
situ gelling of the formulation, which reduces the
potential for drip, modulating fentanyl release compared
to a simple solution.12,28 Two strengths are available
containing either 100or 400 mg fentanyl citrate equivalent.
Preliminary registration studies were performed with
the lowest dose to be titrated against the effect, showing
that both nasal fentanyl preparations provide rapid and
efficient analgesia in comparison with placebo, oral
morphine, or oral transmucosal fentanyl citrate.2,5,9,13,27
These products have different pharmacokinetic pro-
files and availabilities. Although a pharmacokinetic
study has not been performed in which FPNS has been
compared against a simple (non-gelling) nasal solution,
by comparing the pharmacokinetic data from the FPNS
studies to those reported with simple solutions and to
a non-gelling chitosan formulation, on an equivalent
dose basis, FPNS generates a lower Cmax and has a lower
availability, about 60%,29 in comparison with that of
INFS, which is 80 to 90%.6 This means that a 100-mg
dose of INFS will generate a higher Cmax than 100 mg
of FPNS. However, the minimal commercially available
strength of FPNS is 100 mg, which is double that of
INFS, that is, 50 mg. Indeed, these dosages have been simi-
larly suggested to start the treatment in patients tolerant
to 60 mg of oral morphine equivalents, as they would be
equivalents.
The aim of this randomized, crossover study was to
assess analgesia and adverse effects of these 2 nasal prep-
arations for the BTP management. The secondary
outcome was to assess the efficacy and safety of the 2
fentanyl delivery systems by using doses proportional
to the background opioid doses.Methods
Study Design
This randomized, crossover, open-label study was con-
ducted in a high-volume pain relief and supportive care
unit. The study was approved by ethical committee of
University of Palermo, and all patients provided their
informed consent.
Patients
Adults were eligible if they had a diagnosis of cancer,
were receiving opioids at doses equivalent to or greater
than 60 mg oral morphine equivalents per day for back-ground pain, had a background analgesia of mild inten-
sity (#4 on a numerical scale of 0–10), and were
presenting 1 to 3 episodes of BTP per day.
Patients with unstable or uncontrolled pain (having a
background pain intensity >4 on a numerical scale of
0–10) were not eligible for the study. Exclusion criteria
were BTP not primarily related to cancer, past inability
to tolerate fentanyl, treatment withmonoamine oxidase
inhibitors, history of alcohol or substance abuse, an ex-
pected short survival, and cognitive impairment. Other
pharmacologic treatments were maintained if adminis-
tered for at least 2 weeks. Patients with local problems
of the nasal mucosa were also not eligible.Procedures
Consenting patients who met inclusion criteria were
assessed for the first 4 consecutive BTP episodes for 4
consecutive days. Patients admitted to inpatient setting
were treated according to a routine protocol. After es-
tablishing around-the-clock opioid medication, accord-
ing to the opioid titration process, and achieving a
stable analgesia—with mean pain intensity equal to or
less than 4/10 on a numerical pain rating scale from
0 to 10—for 2 consecutive days, patients were instructed
to call for a BTPmedicationwhen their pain got severe or
clearly distinguished from their background pain. BTP
type was described as idiopathic or predictable.
Consecutive episodes were recorded during admission
time. Each patient randomly received INFS or FPNS in
doses proportional to opioids used for background anal-
gesia for 2 pairs of consecutive episodes. For example,
the minimum existing dose of 100 mg of FPNS was given
to patients receiving 60 mg of oral morphine equiva-
lents, 200 mg was given to patients receiving 120 mg of
oral morphine equivalents, and so on. Similarly, in epi-
sodes treated with INFS, patients were administered
50 mg, 100 mg, and so on. For each episode of BTP, nurses
recorded pain intensity (numerical scale of 0–10) and
adverse effects intensity on a scale ranging from 0 to 3
(absent, mild, moderate, and severe) just before starting
INFS or FPNS (T0) and then 5 (T5), 10 (T10), and 20
(T20) minutes after administration of the nasal drugs.
Patients who were unsatisfied with the treatment could
ask to stop the procedure and opt for their previous
effective BTPmedication (mainly intravenousmorphine).Efficacy Measures
The principal outcome was the evaluation of the num-
ber of episodes that benefited from the use of INFS or
FPNS by using proportional doses of the basal opioid
dosage at different point intervals. The administration
of the BTP medication was considered successful when-
ever the decrease in pain intensity was more than 33%
of baseline pain measurement. Secondary end points
were the patient-averaged summed pain intensity differ-
ence 20 minutes after dosing (SPID20), defined as the cu-
mulative sum of the recorded difference between pain
intensity and baseline at each time point from 5 to
20 minutes post dose. Moreover, patients who received
both treatments were asked about their preference.
604 The Journal of Pain Intranasal Fentanyls Are Safe and EffectiveSafety and Tolerability Assessment
Intensity of adverse effects at each point interval was
recorded on a scale from 0 to 3. The occurrence of
adverse effects of moderate to severe intensity (intensity
of 2–3 on a verbal scale) or requiring a medical interven-
tion was recorded.
Statistical Analysis
A sample size of 65 evaluable patients (considering at
least 1 pair of episodes of BTP for a patient to achieve
in a total of 65 pairs of episodes of BTP) yielded a statis-
tical power of 80% with type I error of .05 and would
allow the detection of a difference of 15% in pain inten-
sity score reduction froma baseline of$33%or$50%be-
tween 2 treatment groups with BTP episodes. Statistical
analysis of quantitative data, including descriptive statis-
tics, was performed for all the items. All continuous data
are expressed asmean6 standard deviation of themean.
Frequency analysis was performed using the Pearson’s
chi-square and Fisher exact tests as needed. One-way
analysis of variance and Kruskal-Wallis statistical test
were used to compare the different parametric or
nonparametric variables between the treatment groups.
One-way and mixed-model analyses of variance were
used to examine within- and between-group effects,Figure 1. Studyrespectively, at the different time intervals. Data were
analyzed by using the Epi Info software, version 3.2.2
(Centers for Disease Control and Prevention, Atlanta,
GA), and SPSS, version 21.0 (SPSS, Inc, Chicago, IL). All P
values were 2 sided, and P values less than .05 were
considered statistically significant.Results
A total of 70 patients were screened for the study.
The mean age was 63.4 years (SD = 10.8, range 28–85),
and 37 patients were males. The primary diagnoses
were lung (n = 15), genitourinary (n = 12), gastrointes-
tinal (n = 11), pancreas (n = 9), breast (n = 8), and other
(n = 15). Information on the type of BTP was available
for 46 patients: idiopathic in 28 patients, predictable in
10, and both in 8 patients.
The opioid dose used for background pain, expressed
as mean oral morphine equivalents, was 191.6 mg
(SD = 111.2, range 490).
A flow diagram of the study is presented in Fig 1. One
patient declined to participate. Seven patients did not
receive any study medication: 6 did not have episodes
of BTP for 4 consecutive days, and 1 had poor compli-
ance. Fifteen patients received only 1 study medicationflow chart.
Figure 2. Number of episodes in the 2 groups with a decrease
in pain intensity of >33%or 50%at the different timepoints (T5,
T10, and T20).
Mercadante et al The Journal of Pain 605because they had only 1 episode of BTP (n = 7) or because
they refused to continue to use the nasal route because
of poor satisfaction (n = 1), poor compliance (n = 1),
adverse effects (n = 1), local effects (n = 2), and inefficacy
(n = 1). Data were unavailable in 2 patients. Forty-seven
patients took both study medications. Two groups of 5
patients each had 2 and 3 episodes of BTP, respectively,
and 37 patients had 4 episodes. Globally there were 84
pairs of episodes of BTP to compare. Intravenous
morphinewas used 20minutes after drug administration
in 6 and 7 episodes in INFS and PFNS, respectively.
A total of 188 episodes were treated, of which 91 and
97were administered INFS and PFNS, respectively. No dif-
ferences were found in the number of episodes treated
with the 2 drugs and age (P = .943), gender (P = .959), pri-
mary diagnosis (P = .984), type of opioids used for back-
ground analgesia (P = .415), doses of oral morphine
equivalents used for background pain (P = .132), pain
mechanism (P = .955), and type of BTP (P = .983).
Themean doses of INSTand FPNSwere 165 mg (SD = 97,
range 50–400) and 328 mg (SD = 190, range 100–800),
respectively. The changes in pain intensity (numerical
scale 0–10) after INFS and FPNS at the different time in-
tervals are shown in Table 1.
The number of episodes in the 2 groups with a
decrease in pain intensity >33% and 50%, respectively,
at the different time intervals is presented in Fig 2. Glob-
ally, a decrease in pain intensity of >33% at T5, T10, and
T20 was observed in 16, 102, and 159 treated episodes,
respectively. A statistical difference between INFS and
FPNS was found 5 minutes after the administration
(P = .016). A decrease in pain intensity of >50% at T5,
T10, and T20 was observed in 4, 40, and 126 treated epi-
sodes, respectively. A statistical difference between INFS
and FPNS was found 20 minutes after the administration
(P = .043).
The mean SPID20 values of INFS and FPNS were 6.7
(SD = 3.1) and 7.5 (SD = 4.3), respectively. The difference
was not significant (P = .165).
No differences in changes in pain intensity were found
between episodes treated with $200 mg of INST
or$400mgofFPNSandepisodes treatedwith lowerdoses.
Adverse Effects
Adverse effects were evaluated before administering
the study drugs. The changes in intensity of the principal
adverse effects are shown in Table 2. Adverse effects
were of mild entity in the majority of cases or were pre-
existent because of basal opioid therapy. Only a minority
of patients developed adverse effects of moderate or se-Table 1. Changes in Pain Intensity (Numerical
Scale 0–10) at the Different Time Intervals
T0 T5 T10 T20
FPNS (n = 97) 6.8 (.98) 5.6 (1.10)*,y 4.4 (1.43)* 3.0 (1.71)*,z
INST (n = 91) 6.8 (.83) 5.8 (1.03)* 4.6 (1.36)* 3.4 (1.51)*
*P # .0005 versus T0.
yP = .016 versus INFS.
zP = .043 versus INFS.vere intensity. Five patients reported drowsiness of mod-
erate intensity in more BTP episodes (3 patients with
doses of INST 100, 200, and 400 mg, and 2 patients with
doses of FPNS 400 mg); 2 patients developed nausea of
moderate intensity in more BTP episodes (with INST mg
100). Apart from patients who discontinued the study
(see above), 2 patients developed nasal pruritus (1 after
FPNS, and 1 after INFS).Preference
Forty-two patients provided information about their
preference of the 2 nasal drugs. Most patients did not
find substantial differences (indifferent). Seven patients
preferred FPNS, and 3 patients preferred INST.Discussion
This comparative study has shown that INFS and FPNS
are effective and well-tolerated treatments for BTP man-
agement. Both delivery systems provided fast and signif-
icant analgesia. For example, 50% and 57% of episodes
treated with INFS and FPNS, respectively, had a decrease
in pain intensity of$33% after 10minutes, and 18% and
23% of episodes treated with INFS and FPNS, respec-
tively, had a more consistent decrease in pain intensity
($50%). The level of pain intensity 20 minutes after
administration was about 50% of the pain intensity of
BTP. This change, which mainly corresponded with the
background analgesia, is considered clinically meaning-
ful for patients.24 No preference for 1 of the 2 products
was given by patients who received both delivery systems.Table 2. Changes in Intensity of the Principal
Adverse Effects in the 2 Groups
INFS FPNS
T0 T5 T10 T20 T0 T5 T10 T20
Nausea-vomiting .15 .13 .08 .07 .08 .07 .05 .17*
Drowsiness .44 .46 .60 .63* .43 .49 .53* .54*
Confusion .22 .22 .15 .19 .23 .20 .18 .24
*P < .05.
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in doses proportional to the basal opioid dose used for
background pain were effective as well as tolerable, con-
firming experience accumulated through the years and
the findings of some controlled studies,13-24 even when
higher doses were used. Finally, despite a similar
analgesic trend, FPNS had a major impact at the
intervals taken into consideration.
There are some pharmacologic considerations that
may explain these observations. The similar onset of ac-
tion of FPNS could seem to be unexpected, given the
characteristics of the products. However, although FPNS
generates a lower Cmax for its formulation, modulating
fentanyl absorption, the doses given in this study were
exactly double those of INFS used as the minimal avail-
able strengths commonly employed as starting doses in
titration studies, which are 100 and 50 mg, respectively.
INFS availability has been shown to be 80 to 90%,7
whereas FPNS availability is about 60%.4 At the end,
about 60 and 40 mg will be available at dose strengths
of FPNS 100 and INFS 50 mg, respectively, with one-third
of availability in favor of FPNS. Of interest, a similar anal-
gesic trend was observed at the different dose levels that
were given proportional to the basal opioid. Thus, it is
likely that patients may benefit from similar but not
identical amounts of fentanyl. The presence of a certain
level of tolerance may explain this finding, also with
respect to the occurrence of adverse effects. In patients
responsive to opioids, an opioid dose proportional to
the basal opioid regimen has a predictable therapeutic
window that provides efficacy with limited toxicity.
Thus, opioid tolerance may have a protective role in pa-
tients receiving opioids long-term when fentanyl prod-
ucts are given to rapidly relieve BTP.
Most studies of BTP medication have suggested
titrating the dose of ROOs given for BTP.1 However, these
randomized trials have never specifically examined this
issue, and the information gathered is just consequential
to the study design aimed to demonstrate superiority of
ROOs over placebo, oral morphine, or usual oral opioids,
or to evaluate the safety and efficacy of ascending doses
of ROOs in dose-finding studies.15 Many controversies
surround this issue. Dosing proportional to basic opioid
regimen has been proposed as an alternative to dose
titration.10 A simulation of a calculation of doses of opi-oids used for background analgesia and those achi-
eved after individual titration showed mean values of
proportional doses very close to those found after titra-
tion.20 In a ‘‘real world’’ study reproducing a clinical sce-
nario of patients receiving opioids for BTP, although the
dose of oral opioids used as rescue medication was 18%
of the around-the-clock opioid dose, for oral transmu-
cosal fentanyl titrated to determine the effective dose,
the rescue dose was about 35% of the around-the-clock
dose,30 suggesting that the titration process may provide
even higher doses than those expected by using doses
proportional to the basal regimen. For instance, the only
existing controlled study performed using a fentanyl
buccal tablet has evidenced that proportional doses are
more effective than the dose titration approach, without
higher risks of adverse effects,22 confirming a series of
open-label studies inwhich proportional doseswerehigh-
ly effective and well tolerated.13-25
Finally, there is clinical legend suggesting that the
rescue dose of opioids for BTP should be 10%of the daily
dose of scheduled opioids. Several studies of propor-
tional doses have shown that to produce meaningful
and clinical analgesic effects, it is necessary to administer
15 to 20% of the daily dose.13-24
Limitations of this study lie in the lack of blinding.
Moreover, such types of studies are complex and require
economic support from the pharmaceutical industry,
which was not involved in our case. The study was also
designed to assess patients’ preferences. Incomplete
data are common in such studies. However, the number
of pairs of episodes with both treatments was adequate.
In conclusion, INFS and FPNS were effective and well-
tolerated treatments for BTPmanagement. Both delivery
systems, in doses proportional to the basal opioid
regimen, provided significant analgesia within 5 to
10 minutes, achieving a mean decrease of more than
50% in pain intensity 20 minutes after administration,
without producing relevant adverse effects.Acknowledgments
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